Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
University of Pittsburgh
Instituto do Cancer do Estado de São Paulo
EpicentRx, Inc.
Hoffmann-La Roche
Stanford University